| dc.contributor.author | Stevens, Lindsey | |
| dc.contributor.author | Ardeshna, Kirit M. | |
| dc.contributor.author | Qian, Wendi | |
| dc.contributor.author | Smith, Paul | |
| dc.contributor.author | Braganca, Nivette | |
| dc.contributor.author | Lowry, Lisa | |
| dc.contributor.author | Patrick, Pip | |
| dc.contributor.author | Warden, June | |
| dc.contributor.author | Pocock, Christopher F. E. | |
| dc.contributor.author | Linch, David C. | |
| dc.contributor.author | Bradstock, Ken | |
| dc.contributor.author | Ferhanoglu, Burhan | |
| dc.contributor.author | Walewski, Jan | |
| dc.contributor.author | Stephens, Richard | |
| dc.contributor.author | Jack, Andrew | |
| dc.contributor.author | Davies, John | |
| dc.contributor.author | Cunningham, David | |
| dc.contributor.author | Miall, Fiona | |
| dc.date.accessioned | 2021-03-04T10:59:44Z | |
| dc.date.available | 2021-03-04T10:59:44Z | |
| dc.date.issued | 2014 | |
| dc.identifier.citation | Ardeshna K. M. , Qian W., Smith P., Braganca N., Lowry L., Patrick P., Warden J., Stevens L., Pocock C. F. E. , Miall F., et al., "Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial", LANCET ONCOLOGY, cilt.15, sa.4, ss.424-435, 2014 | |
| dc.identifier.issn | 1470-2045 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_70083884-a790-47ac-938f-2675b4c905a9 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/77257 | |
| dc.identifier.uri | https://doi.org/10.1016/s1470-2045(14)70027-0 | |
| dc.description.abstract | Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchful waiting until disease progression. We assessed whether rituximab use could delay the need for chemotherapy or radiotherapy compared with watchful waiting and the effect of this strategy on quality of life (QoL). | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Onkoloji | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.title | Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial | |
| dc.type | Makale | |
| dc.relation.journal | LANCET ONCOLOGY | |
| dc.contributor.department | University College London Hospitals NHS Foundation Trust , , | |
| dc.identifier.volume | 15 | |
| dc.identifier.issue | 4 | |
| dc.identifier.startpage | 424 | |
| dc.identifier.endpage | 435 | |
| dc.contributor.firstauthorID | 214155 | |